Skip to main
COGT
COGT logo

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences Inc. is positioned for significant growth, with 2025 anticipated as a pivotal year that may enhance its attractiveness for mergers and acquisitions, particularly influenced by the outcomes of the APEX and PEAK trials. The company has markedly increased its probability of approval for its therapy bezuclastinib when combined with Sutent in second-line gastrointestinal stromal tumors, now estimated at 90%, alongside an upgraded peak penetration rate to 35%. The encouraging results from the APEX, PEAK, and SUMMIT trials suggest that bezuclastinib could establish itself as a competitive treatment across various malignancies, supporting a strong outlook for Cogent's financial performance.

Bears say

Cogent Biosciences is projecting a significant net loss of $2.28 per share for the full year of 2025, indicating persistent financial challenges. The company faces numerous risks, including negative clinical data for key therapies, slower development timelines, and potential regulatory setbacks, all of which could hinder its ability to achieve commercial success. Additionally, concerns regarding long-term dilution risk further contribute to a negative outlook on the company’s financial stability.

COGT has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 11 analysts, COGT has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.